SCHEMBL7350757

SCHEMBL7350757

COc1ccc(S(=O)(=O)N(Cc2ccccc2)C2(C(=O)NO)CCN(C(=O)OC(C)(C)C)CC2)cc1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 13/20 0.48
MMP1 P03956 11/20 0.48
MMP9 P14780 11/20 0.48
ADAM17 P78536 8/20 0.48
MMP2 P08253 1/20 0.46
BMP1 P13497 2/20 0.46
STS P08842 1/20 0.46
MEN1 O00255 1/20 0.46
LMNA P02545 1/20 0.46
KMT2A Q03164 1/20 0.46
MMP3 P08254 1/20 0.45
MMP7 P09237 1/20 0.45
PTGES O14684 1/20 0.45
TAS2R14 Q9NYV8 1/20 0.45
TAS2R8 Q9NYW2 1/20 0.45
CXCR3 P49682 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7344272 0.92 BMP1 (0.45) MMP13MMP1MMP9ADAM17MMP2
Hydrochloric Acid SCHEMBL7350069 0.87 MMP9 (0.47) MMP13MMP1MMP9ADAM17BMP1
Hydrochloric Acid SCHEMBL7349750 0.86 MMP9 (0.54) MMP13MMP1MMP9ADAM17BMP1
SCHEMBL7349061 0.85 MMP1 (0.67) MMP13MMP1MMP9ADAM17MMP2
SCHEMBL7345287 0.85 MMP9 (0.52) MMP13MMP1MMP9ADAM17BMP1
Hydrochloric Acid SCHEMBL7350073 0.84 MMP1 (0.48) MMP13MMP1MMP9ADAM17MMP2
SCHEMBL7350800 0.84 BMP1 (0.54) MMP13MMP1MMP9ADAM17BMP1
SCHEMBL7348771 0.83 BMP1 (0.53) MMP13MMP1MMP9ADAM17BMP1
Hydrochloric Acid SCHEMBL7343730 0.82 MMP1 (0.54) MMP13MMP1MMP9ADAM17BMP1
SCHEMBL7349249 0.82 BMP1 (0.52) MMP13MMP1MMP9ADAM17MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0766672-B1 ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS NOVARTIS AG (CH) 2000-10-04 EP disclosed
EP-0606046-B1 Arylsulfonamido-substituted hydroxamic acids CIBA GEIGY AG (CH) 1997-10-08 EP disclosed
US-5646167-A ADMINISTERED AS METALLOPROTEINASE INHIBITOR, ANTITUMOR OR ANTICARCINOGENIC AGENT CIBA-GEIGY CORPORATION (US) 1997-07-08 US disclosed
EP-0766672-A1 ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS Novartis AG (CH) 1997-04-09 EP disclosed
WO-1996040101-A1 CERTAIN ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS FOR THE TREATMENT OF CERTAIN TUMORS NOVARTIS AG (CH) 1996-12-19 WO disclosed
US-5552419-A METALLOPROTEINASE INHIBITORS CIBA-GEIGY CORPORATION (US) 1996-09-03 US disclosed
US-5506242-A METALLOELASTASE INHIBITOR; TREATS EMPHYSEMA CIBA-GEIGY CORPORATION (US) 1996-04-09 US disclosed
WO-1996000214-A1 ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS CIBA-GEIGY AG (CH) 1996-01-04 WO disclosed
US-5455258-A Useful as inhibitors of matrix-degrading metalloproteinase enzymes such as stromelysin and/or collegenase CIBA-GEIGY CORPORATION (US) 1995-10-03 US disclosed
EP-0606046-A1 Arylsulfonamido-substituted hydroxamic acids CIBA-GEIGY AG (CH) 1994-07-13 EP disclosed